Regeneron Pharmaceuticals (REGN) Competitors $743.35 -1.25 (-0.17%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends REGN vs. AGN, ALXN, BGNE, RPRX, CTLT, AMGN, VRTX, GILD, ALNY, and BIIBShould you be buying Regeneron Pharmaceuticals stock or one of its competitors? The main competitors of Regeneron Pharmaceuticals include Allergan (AGN), Alexion Pharmaceuticals (ALXN), BeiGene (BGNE), Royalty Pharma (RPRX), Catalent (CTLT), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), Alnylam Pharmaceuticals (ALNY), and Biogen (BIIB). Regeneron Pharmaceuticals vs. Allergan Alexion Pharmaceuticals BeiGene Royalty Pharma Catalent Amgen Vertex Pharmaceuticals Gilead Sciences Alnylam Pharmaceuticals Biogen Allergan (NYSE:AGN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings. Which has better earnings and valuation, AGN or REGN? Regeneron Pharmaceuticals has lower revenue, but higher earnings than Allergan. Allergan is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllergan$16.09B3.95-$5.27B$17.6410.94Regeneron Pharmaceuticals$13.85B5.90$3.95B$40.4118.40 Is AGN or REGN more profitable? Regeneron Pharmaceuticals has a net margin of 33.61% compared to Allergan's net margin of -15.44%. Regeneron Pharmaceuticals' return on equity of 16.88% beat Allergan's return on equity.Company Net Margins Return on Equity Return on Assets Allergan-15.44% 8.46% 5.31% Regeneron Pharmaceuticals 33.61%16.88%13.23% Do insiders & institutionals believe in AGN or REGN? 83.9% of Allergan shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.1% of Allergan shares are owned by insiders. Comparatively, 7.5% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts rate AGN or REGN? Regeneron Pharmaceuticals has a consensus price target of $1,099.55, indicating a potential upside of 47.92%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Allergan.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allergan 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Regeneron Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.78 Does the media favor AGN or REGN? In the previous week, Regeneron Pharmaceuticals had 32 more articles in the media than Allergan. MarketBeat recorded 32 mentions for Regeneron Pharmaceuticals and 0 mentions for Allergan. Regeneron Pharmaceuticals' average media sentiment score of 0.94 beat Allergan's score of 0.00 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Allergan Neutral Regeneron Pharmaceuticals Positive Which has more volatility and risk, AGN or REGN? Allergan has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Does the MarketBeat Community believe in AGN or REGN? Regeneron Pharmaceuticals received 158 more outperform votes than Allergan when rated by MarketBeat users. However, 79.88% of users gave Allergan an outperform vote while only 67.07% of users gave Regeneron Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAllerganOutperform Votes138279.88% Underperform Votes34820.12% Regeneron PharmaceuticalsOutperform Votes154067.07% Underperform Votes75632.93% SummaryRegeneron Pharmaceuticals beats Allergan on 15 of the 19 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REGN vs. The Competition Export to ExcelMetricRegeneron PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$81.82B$6.45B$5.06B$8.82BDividend YieldN/A8.11%5.18%4.07%P/E Ratio18.4010.78126.3117.81Price / Sales5.90243.711,178.7474.56Price / Cash17.4922.1633.8632.53Price / Book3.145.474.684.68Net Income$3.95B$153.61M$119.54M$226.08M7 Day Performance-5.00%-2.00%-1.83%-1.04%1 Month Performance-23.25%-7.46%-3.60%1.04%1 Year Performance-6.95%31.82%31.91%26.28% Regeneron Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REGNRegeneron Pharmaceuticals4.786 of 5 stars$743.35-0.2%$1,099.55+47.9%-7.3%$81.82B$13.12B18.4013,450AGNAllerganN/A$193.02flatN/A+0.0%$63.50B$16.09B10.9417,400High Trading VolumeALXNAlexion PharmaceuticalsN/A$182.50flatN/A+0.0%$40.34B$6.07B15.733,837BGNEBeiGene3.174 of 5 stars$194.26+3.5%$247.07+27.2%+3.4%$18.92B$2.46B-23.5810,600Analyst DowngradeGap UpRPRXRoyalty Pharma4.7172 of 5 stars$26.22+0.8%$41.67+58.9%-2.6%$15.32B$2.36B13.5980CTLTCatalent3.03 of 5 stars$59.00+0.2%$63.40+7.5%+47.8%$10.71B$4.38B-26.1116,900AMGNAmgen4.9084 of 5 stars$287.87+2.8%$333.57+15.9%+8.5%$154.74B$28.19B36.8626,700Ex-DividendShort Interest ↓VRTXVertex Pharmaceuticals4.0443 of 5 stars$451.23+0.7%$499.12+10.6%+26.5%$115.38B$9.87B0.005,400Analyst DowngradePositive NewsGILDGilead Sciences4.549 of 5 stars$88.63+1.0%$94.00+6.1%+16.6%$109.36B$27.12B984.7818,000Analyst ForecastPositive NewsALNYAlnylam Pharmaceuticals4.3868 of 5 stars$248.79+6.2%$298.09+19.8%+50.5%$32.09B$1.83B-94.962,100Analyst ForecastBIIBBiogen4.8601 of 5 stars$156.00+0.4%$258.96+66.0%-32.2%$22.65B$9.84B14.097,570Analyst Downgrade Related Companies and Tools Related Companies Allergan Alternatives Alexion Pharmaceuticals Alternatives BeiGene Alternatives Royalty Pharma Alternatives Catalent Alternatives Amgen Alternatives Vertex Pharmaceuticals Alternatives Gilead Sciences Alternatives Alnylam Pharmaceuticals Alternatives Biogen Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:REGN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free REGN Stock Alerts